codon optimized cas9  (Addgene inc)

Journal: iScience

Article Title: Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma

doi: 10.1016/j.isci.2025.112387

Figure Lengend Snippet: Deletion of HOPX impairs the progress of DTP regrowth (A) Western blot showing reduction of HOPX expression in PC9 cells by CRISPR-Cas9 mediated deletion of HOPX gene. (B) Cell growth curve of PC9 cells transfected with sgRNAs targeting HOPX or non-target sgRNAs. (C) Cell viability of PC9 cells transfected with sgRNAs targeting HOPX or non-target sgRNAs under the treatment of 150nM osimertinib at indicated time points (normalized to day0). Right: Bar graph showing cell viability at day 28 ( n = 4, including duplicates for sgRNA1 and duplicates for sgRNA2). (D) Colony formation assay on PC9 cells, at seeding density of 150,000 cells/well under 150nM osimertinib starting at 24 h after seeding. Left: Two representative images taken at 20 days after treatment per condition. Right: Quantification of colony numbers based on the representative fields shown on the left ( n = 4), including duplicates for sgRNA1 and duplicates for sgRNA2. (E) Western blot showing reduction of HOPX expression in NCI-H358 cells. (F) Cell growth of NCI-H358 cells transfected with sgRNAs targeting HOPX or non-target sgRNAs. (G) Cell viability of NCI-H358 cells transfected with sgRNAs targeting HOPX or non-target sgRNAs under the treatment of 500nM sotorasib at indicated time points (normalized to day 0). Right: Bar graph showing cell viability at day 25 ( n = 4, including duplicates for sgRNA1 and duplicates for sgRNA2). (H) Colony formation assay on NCI-H358 cells, at seeding density of 150,000 cells/well under 500nM sotorasib starting at 24 h after seeding. Left: Two representative images taken at 20 days after treatment per condition. Right: Quantification of colony numbers based on the representative fields shown on the left ( n = 4), including duplicates for sgRNA1 and duplicates for sgRNA2. Data are presented as means ± S.D. ( n = 4). Statistical significance was determined using Mann-Whitney test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: Cells stably expressing human codon-optimized S. pyogenes Cas9 expression were generated by infection with the lentiCas9-Blast plasmid (a gift from Feng Zhang, Addgene #52962). sgRNAs targeting HOPX (selected from Brunello library) and non-target sgRNAs (selected from the Gecko library v2) were synthesized by Integrated DNA Technologies and listed in sgRNAs were cloned into lentiGuide-Puro (Addgene #52963) at Esp3I site.

Techniques: Western Blot, Expressing, CRISPR, Transfection, Colony Assay, MANN-WHITNEY

Journal: International Journal of Pharmaceutics: X

Article Title: Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery

doi: 10.1016/j.ijpx.2024.100283

Figure Lengend Snippet: Summary of ongoing or completed clinical trials utilizing LNPs. Formulation information is provided anywhere possible. Additional sources used in the construction of this table: https://clinicaltrials.gov ; https://classic.clinicaltrials.gov ; https://www.cdek.liu.edu . N/A: Formulation information not found, or any information identified were not peer-reviewed and not included.

Article Snippet: NTLA-2001 , NCT04601051 NCT06128629 , Phase 1 (2020–2026) Phase 3 (2023–2028) , LNP-encapsulated single guide RNA (sgRNA) targeting human TTR and a human-codon optimized mRNA sequence of S. pyogens Cas9 protein , N/A , Transthyretin (ATTR) amyloidosis with cardiomyopathy , IV , ( ) , Intellia Therapeutics , Active, not recruiting Recruiting.

Techniques: Formulation, Virus, Membrane, Binding Assay, Recombinant, Vaccines, Modification, Infection, Expressing, Small Interfering RNA, CRISPR, Sequencing